Monoclonal Antibodies for the Treatment of Hematologic Malignancies: Schedule and Maintenance Therapy

Seminars in Hematology

Volumn 45, Issue 2, 2008, Pages 75-84

  Moccia, Alden ^a   Ghielmini, Michele ^a  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GEMTUZUMAB OZOGAMICIN; MONOCLONAL ANTIBODY; PARACETAMOL; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEVER; FOLLICULAR LYMPHOMA; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOTENSION; LYMPHOCYTOMA; MAINTENANCE THERAPY; MONOTHERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RASH; RESPIRATORY FAILURE; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; TREATMENT DURATION; VOMITING;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; HEMATOLOGIC NEOPLASMS; HUMANS; REMISSION INDUCTION; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 41149180913     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.02.006     Document Type: Article

References (74)

1. Maloney D.G., Liles T.M., Czerwinski D.K., Waldichuk C., Rosenberg J., Grillo-Lopez A., et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84 (1994) 2457-2466
2. Rose A.L., Smith B.E., and Maloney D.G. Glucocorticoids and rituximab in vitro; synergistic direct antiproliferative and apoptotic effects. Blood 100 (2002) 1765-1773
3. Berinstein N.L., Grillo-López A.J., White C.A., Bence-Bruckler I., Maloney D., Czuczman M., et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9 (1998) 995-1001
4. Maloney D., Grillo-Lopez A., Bodkin D., White C., Liles T., Royston I., et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15 (1997) 3266-3274
5. McLaughlin P., Grillo-López A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
6. Coiffier B., Haioun C., Ketterer N., Engert A., Tilly D., Johnson P., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92 (1998) 1927-1932
7. O'Brien S.M., Kantarjian H., Thomas D.A., Giles F.J., Freirech E.J., Cortes J., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19 (2001) 2165-2170
8. Manshouri T., Do K., Wang X., Giles F.J., O'Brien S.M., Saffer H., et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101 (2003) 2507-2513
9. Piro L.D., White C.A., Grillo-López A.J., Janakiraman N., Saven A., Beck T.M., et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10 (1999) 655-661
10. Bremer K. Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell non-Hodgkin's lymphoma: A phase II study. Anticancer Drugs 14 (2003) 809-815
11. Gordan L.N., Grow W.B., Pusateri A., Douglas V., Mendenhall N.P., and Lynch J.W. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 23 (2005) 1096-1102
12. Czuczman M.S., Grillo-López A.J., White C.A., Saleh M., Gordon A., LoBuglio A.F., et al. Treatment of patients with low-grade B-Cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17 (1999) 268-276
13. Byrd J.C., Murphy T., Howard R.S., Lucas M.S., Goodrich A., Pearson M., et al. Rituximab using a Thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19 (2001) 2153-2164
14. Sehn L.H., Donaldson J., Filewich A., Fitzgerald C., Gill K.K., Runzer N., et al. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can be safely be delivered in the community setting. Blood 109 (2007) 4171-4173
15. Salar A., Casao D., Cervera M., Pedro C., Calafell M., Abella E., et al. Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution. Eur J Haematol 77 (2006) 338-340
16. Siano M, Lerch E, Zucca E, Mora O, Sessa C, Ghielmini M: A phase I-II study to determine the maximum tolerated infusion-rate of rituximab, with a special emphasis on monitoring the effect of rituximab on cardiac function. ASH abstr 3411.
17. Hainsworth J.D., Litschy S., Burris III H.A., Scullin Jr. D.C., Corso S.W., Yardley D.A., et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 4261-4267
18. Hainsworth J.D., Litschy S., Lamb M.R., Rodriguez G.I., Scroggin Jr. C., and Greco F.A. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21 (2003) 1746-1751
19. Hainsworth J.D., Litchy S., Shaffer D.W., Lackey V.L., Grimaldi M., and Greco F.A. Maximizing therapeutic benefit of rituximab: Maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma: A randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23 (2005) 1088-1095
20. Ghielmini M., Hsu-Schmitz S.F., Cogliatti S.B., Pichert G., Hummerjohann J., Walzer U., et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103 (2004) 4416-4423
21. Ghielmini M., Hsu-Schmitz S., Cogliatti S., Bertoni F., Waltzer U., Fey M.F., et al. Effect of single-agent Rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 4 (2005) 705-711
22. Hochster H.S., Weller E., Ryan T., Habermann T.M., Gascoyne R., Frankel S.R., et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J Clin Oncol 22 suppl (2004) 558s (abstr)
23. Hochster H.S., Weller E., Gascoyne R.D., Ryan T.S., Habermann T.M., Gordon L.I., et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 106 (2005) 106a (abstr)
24. Hagenbeek A., Van Glabbeke M., Teodorovic I., et al. The role of rituximab maintenance treatment in relapsed follicular NHL: An interim analysis of the EORTC randomized intergroup trial. Ann Oncol 16 (2005) v52 (abstr)
25. Habermann T.M., Weller E., Morrison V.A., et al. Rituximab-CHOP versus CHOP with or withou maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): An update. Blood 104 (2004) 40a (abstr 127)
26. Forstpointner R., Dreyling M., Repp R., Hermann S., Hanel A., Metzner B., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide and mitoxantrone (FCM) significantly prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphoma-Results of a prospective randomized study of the German Low Grade Lymphoma Study Group. Blood 104 (2004) 3064-3071
27. van Oers M.H.J., Klasa R., Marcus R.E., Wolf M., Kimby E., Gascoyne R.D., et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: Results of a prospective randomized phase III intergroup trial. Blood 108 (2006) 3295-3301
28. Brugger W., Hirsch J., Grüneback F., Repp R., Brossart P., Vogel W., et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: A prospective multicenter phase II study. Ann Oncol 15 (2004) 1691-1698
29. Mangel J., Leitch H.A., Connors J.M., Buckstein R., Imrie K., Spaner D., et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle cell lymphoma: A matched pair analysis. Ann Oncol 15 (2004) 283-290
30. Neumann F., Harnsen S., Martin S., Kronenwett R., Kondakei M., Aivado M., et al. Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B cell non-Hodgkin's lymphoma. Ann Hematol 85 (2006) 530-534
31. Gilleece M.H., and Dexter T.M. Effect of Campath-H1 antibody on human hematopoietic progenitors in vitro. Blood 82 (1993) 807-812
32. Heit W., Bunjes D., Wiesneth M., Schmeiser T., Arnold R., Hale G., et al. Ex vivo T cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft versus-host disease in allogeneic bone marrow transplantation. Br J Haematol 64 (1986) 479-486
33. Dyer M.J., Hale G., Hayhoe F.G., and Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73 (1989) 1431-1439
34. Rowan W., Tite J., Topley P., and Brett S.J. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 95 (1998) 427-436
35. Xia M.Q., Hale G., and Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol 30 (1993) 1089-1096
36. Riechmann L., Clark M., Waldmann H., and Winter G. Reshaping human antibodies for therapy. Nature 332 (1988) 323-327
37. Golay J., Manganini M., Rambaldi A., and Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica 89 (2004) 1476-1483
38. Mould D.R., Baumann A., Kuhlmann J., Keating M.J., Weitman S., Hillmen, et al. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukemia and its link to treatment response. Br J Clin Pharmacol 64 (2007) 278-291
39. Montillo M., Tedeschi A., Miqueleiz S., Veronese S., Cairoli R., Intropido L., et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymhpocytic leucemia. J Clin Oncol 24 (2006) 2337-2342
40. Hale G., Dyer M.J.S., Clark M.R., Philipps J.M., Marcus R., Riechmann L., et al. Remission induction in non-Hodgkin lymphoma with reshaped human antibody CAMPATH-1H. Lancet 2 (1988) 1394-1399
41. Osterborg A., Dyer M.J., Bunjes D., Pangalis G.A., Bastion Y., Catovsky D., et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15 (1997) 1567-1574
42. Rai K.R., Freter C.E., Mercier R.J., Cooper M.R., Mitchell B.S., Stadtmauer E.A., et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20 (2002) 3891-3897
43. Keating M.J., Flinn I., Jain V., Binet J.L., Hillmen P., Byrd J., et al. Therapeutic role of alemtuzumab (campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 99 (2002) 3554-3561
44. Pawson R., Dyer M.J.S., Barge R., Matutes E., Thomton P.D., Emmett E., et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 15 (1997) 2667-2672
45. Dearden C.E., Matutes E., Cazin B., Tjonnfjord G.E., Parreira A., Nomdedeu B., et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98 (2001) 1721-1726
46. Keating M.J., Cazin B., Coutré S., Birhray R., Kovacsovics T., Langer B., et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 20 (2001) 205-213
47. Enblad G., Hagberg H., Erlanson M., Lundin J., MacDonald A.P., Repp R., et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103 (2004) 2920-2924
48. Zinzani P.L., Alinari L., Tani M., Fina M., Pileri S., and Baccarani M. Preliminary observations of a phase II study of reduced-dose alemtuzumab in patients with pretreated T-cell lymphoma. Haematologica 90 (2005) 702-703
49. Cull G., Haynes A.P., Byrne J.L., Carter G.I., Miflin G., Rebello P., et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disease using BEAM-CAMPATH conditioning: an effective regimen with low procedure related toxicity. Br J Haematol 108 (2000) 754-760
50. Hale G., Rebello P., Brettman L.R., Fegan C., Kennedy B., Kimby E., et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104 (2004) 948-955
51. Lundin J., Kimby E., Bjorkholm M., Broliden P.A., Celsing F., Hjalmar V., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100 (2002) 768-773
52. Bowen A.L., Zomas A., Emmett E., Matutes E., Dyer M.J., and Catovsky D. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukemia. Br J Haematol 96 (1997) 617-619
53. Rai K.R., Jonson D., Driscoll N., Crowley A., and Ahmed S. Varyng modes of maintenance therapy with CAMPATH-1H in chronic lymphocytic leukemia. Proc Am Soc Clin Oncol 21 (2002) 275a (abstr)
54. Wendtner C.M., Ritgen M., Schweighofer C.D., Fingerle-Rowson G., Campe H., Jager G., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission: Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18 (2004) 1093-1101
55. O'Brien S.M., Kantarjian H.M., Thomas D.A., Cortes J., Giles F.J., Wierda W.G., et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98 (2003) 2657-2663
56. Linenberger M.L., Hong T., Flowers D., Sievers E.L., Gooley T.A., Bennett M.S., et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98 (2001) 988-994
57. Sievers E.L., Larson R.A., Stadtmauer E.A., Estey E., Lowenberg B., Dombret H., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. J Clin Oncol 19 (2001) 3244-3254
58. Golay J., Di Gaetano N., Amico D., Cittera E., Barbui A.M., Giavazzi R., et al. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukaemias in vitro and in vivo. Br J Haematol 128 (2005) 310-317
59. Amico D., Barbui A.M., Erba E., Rambaldi A., Introna M., and Golay J. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: Role of Chk1 and Chk2 phosphorylation and caspase 3. Blood 101 (2003) 4589-4597
60. Sievers E.L., Appelbaum F.R., Spielberger R.T., Forman S.J., Flowers D., Smith F.O., et al. Selective ablation of acute myeloid leukemia using antibodytargeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93 (1999) 3678-3684
61. Sievers E.L., Larson R.A., Stadtmauer E.A., Estey E., Lowenberg B., Dombret H., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 19 (2001) 3244-3254
62. Taksin A.L., Legrand O., Raffoux E., de Revel T., Thomas X., Contentin N., et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the Alfa group. Leukemia 21 (2007) 66-71
63. van der Velden V.H.J., te Marvelde J.G., Hoogeveen P.G., Bernstein I.D., Houtsmuller A.B., Berger A.S., et al. Targeting of the CD33- calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97 (2001) 3197-3204
64. Dowell J.A., Korth-Bradley J., Liu H., King S.P., and Berger M.S. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 41 (2001) 1206-1214
65. Thomas X., Le Q.H., Tavernier E., Mahmoudi S., Chelghoum Y., Nicolini F., et al. Gemtuzumab ozogamicin (Mylotargs) as single agent treatment for adult patients with acute myeloid leukemia (AML). Blood 106 (2005) 4598 (abstr)
66. Larson R.A., Boogaerts M., Estey E., Karanes C., Stadtmauer E.A., Sievers E.L., et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 16 (2002) 1627-1636
67. Lundin J., Österborg A., Brittinger G., Crowther D., Dombret A., Engert A., et al. CAMPATH-1H monoclonal antibody in therapy for previous treated low-grade non-Hodgkin's lymphomz: A phase II multicenter study. J Clin Oncol 16 (1998) 3257-3262
68. Montillo M., Cafro A.M., Tedeschi A., Brando B., Oreste P., Veronese S., et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leucemia responding to fludarabine. Haematologica 87 (2002) 695-700
69. Moreton P., Kennedy B., Lucas G., Leach M., Rassam S.M.B., Haynes A., et al. Eradication of minimal residual disease in B-cell chronic lymhocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23 (2005) 2971-2979
70. Piccaluga P.P., Martinelli G., Rondoni M., Malagola M., Gaitani S., Isidori A., et al. Gemtuzumeb ozogamicin for relapsed and refractory acute myeioid leukemia and myeloid sarcomas. Leuk Lymphoma 45 (2004) 1791-1795
71. Larson R.A., Sievers E.L., Stadtmauer E.A., Lowenberg B., Estey E.H., Dombret H., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myelcid leukemia in first recurrence. Cancer 104 (2005) 1442-1452
72. Amadori S., Suciu S., Stasi R., Willemze R., Mandelli F., Sellesiag D., et al. Gemtuzumab ozogamicin as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: Final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leucemia Groups. Leukemia 19 (2005) 1768-1773
73. Nebhan C., Rundhaugen L.M., Riley M.B., Rademaker A., Boehike L., Jatoi M., et al. Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leuk Res 29 (2005) 53-57
74. Van der Heiden P.L., Jedema I., Willemze R., and Barge R.M. Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Eur J Haematol 76 (2006) 409-413